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who received SGN-CD33A, had anti-leukemic beneﬁt, and
went to allogeneic SCT.
Results: Case 1: A 37-year-old male with AML (inter-
mediate risk cytogenetics) achieved CR with standard in-
duction/consolidation May 2013. He relapsed Dec 2013
and got decitabine before enrolling in SGN33A-001 Jan 2014
(20 mcg/kg). He had ECOG 1, G4 neutropenia, G3 throm-
bocytopenia, and 6-8% blasts. D15 marrow showed a
hypocellularity with no evidence of leukemia. He remained
pancytopenic and his marrow hypoplastic with no evidence
of AML until residual leukemia was identiﬁed at 6.6% by
ﬂow cytometry in hypocellular marrow Mar 2014. He had a
double cord transplant Apr 2014 with ﬂudarabine, cytoxan,
and TBI conditioning regimen. D30 and D100 posttransplant
marrow had no AML and 100% donor chimerism. He is now
5 months posttransplant with no AEs related to SGN-
CD33A.
Case 2: A 41-year-old male with normal karyotype AML
(nucleophosmin cytoplasmic and IDH2 mutations) achieved
CR with high-dose cytarabine + idarubicin induction Jul
2013 which was complicated by acute renal failure requiring
hemodialysis. He had 4 cycles of idarubicin + cytarabine
consolidation. He relapsed Apr 2014 and enrolled in
SGN33A-001 (60 mcg/kg). He had ECOG 0, G3 neutropenia,
and G2 thrombocytopenia. The marrow was 10-20% cellular
with 50% CD33+ blasts. D15 marrow was <5% cellular
without AML. He experienced cellulitis with lymphangitis,
Staphylococcus aureus bacteremia, and persistent fever with
cavitary pulmonary nodules. He had prolonged pancyto-
penia; D64marrowwas< 5% with pockets of hematopoiesis.
He had ﬂudarabine and busulfan conditioning regimen and
MRD allo HSCT complicated by severe mucositis. He had
neutrophil recovery by D16. D30 marrow had no AML and
100% donor chimerism. He is doing well at D75.
Conclusions: These case reports support the anti-leukemic
activity of SGN-CD33A and enablement of allogeneic SCT.
This trial is ongoing to deﬁne MTD and optimize dose and
schedule. Combinations of SGN-CD33A with standard AML
and MDS agents are planned.241
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Introduction: Allogeneic transplantation is the only curative
option for patients with high risk leukemias or MDS. Only
one third of them have an HLA identical sibling donor and
around 60-70% will ﬁnd an unrelated donor; that’s why
haploidentical stem cell transplantation (HAPLO-HSCT) of-
fers a therapeutic option to most of these patients. Myeloa-
blative conditioning (MAC) used to obtain better diseasecontrol than reduced intensity conditioning regimens (RIC),
but with higher toxicity, rendering long term similar results.
Patients and Methods: We retrospectively evaluated the
results in patients diagnosed with high risk leukemias or
MDS of ourMAC-HAPLO regimens (Fludarabine 30mg/m2 x5
days (-6 to -2), Cyclophosphamide14,5 mg/kg x2 days (-6 to
-5), IV Busulfan 3,2 mg/kg x 3 days (BUX3) on days -4 to -2, or
Fludarabine 40 mg/m2 x4 days (-6 to -2) and IV Busulfan 3,2
mg/kg x 4 days (BUX4)) with GVHD prophylaxis based on
PT-CY (50 mg/kg on days +3 and +4) and a calcineurin in-
hibitor plus mycophenolate from day +5, performed in GETH
centers.
Results: From Feb 2011, 24 MAC-HAPLO have been done in 7
centers. Median age was 37 years (15-65), 58% were males
and all were in advanced disease phase or presented high
risk features (AML 16/ALL 4/MDS 2/ CML-BC 1/ CMML 1).
Previous HSCT had been employed in 21% (autologous in 1,
allogeneic in 4), and in 79% the HAPLO-HSCT was their ﬁrst
transplant. Disease status at HAPLO-HSCT was morphologic
CR in 83%, but with persistent disease (morphologic or
MRD+ by ﬂow or molecular markers) in 67%. BM was the
graft source in 3 patients (12.5%) and PBSC in 21 (87.5%), non
T-cell depleted in all cases. The haploidentical donor was the
patient’s mother (21%), father (12.5%), siblings (41.5%) or
offspring (25%). MAC regimenwas BUX3 in 8 (33%) and BUX4
in 16 patients (67%). Median infused CD34+ cells were
4,93x10e6/kg (3,20-8,43). Median neutrophils engraftment
was reached at day +16 (13-29) and platelets >20K at day
+27 (11-131). Complete chimerismwas obtained at a median
of 22 days (13-44) in 21 evaluated patients. Cumulative
incidence (CI) of non-relapse mortality (NRM) was 21.5% at 1
year. CI of grade II-IV acute GVHDwas 45.5% at day +100, and
grade III-IV was 9%. CI of chronic GVHD at 1 year was 35%,
being extensive in 8% . No differences in acute or chronic
GvHD CI were seen when comparing BUX3 against BUX4.
After a median follow-up of 15 months (3-31), estimated
18-months event-free survival (EFS) and overall survival
(OS) were 63% and 75% respectively. CI of relapse or pro-
gression was 19.5%. No signiﬁcant differences in NRM, EFS,
OS and relapse incidence were detected between BUX3 and
BUX4. The effect of CR prior to MAC-HAPLO has not been
appropriately assessed due to the limited number of events
in our series.
Conclusions: IV Busulfan based MAC-HAPLO with PT-CY in
the treatment of high risk leukemias and MDS offers good
disease control with manageable toxicity, with either BUX3
or BUX4.242
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Table 1
Racial distribution of study population
Chinese Malay Indian Others
Frequency 314 53 7 17
Percentage (80.3%) (13.6%) (1.8%) (4.3%)
Table 2
Summary of primary and secondary outcomes
No of conventional
induction
chemotherapy
Patients who achieved CR
One cycle
(n¼245)
Two cycles
(n¼61)
> 2 cycles
(Primary Resistant
AML) (n¼7)
CR rate (%) 65.7 15.6 1.8
Duration of CR (days)
Median 273 209 206
Range (183 e 468) (114 e 562) (173 e 301)
Relapse rate (%) 42.4 40.9 85.7
Undergone
hematopoietic
stem cell
transplantation (%)
56.3 60.7 85.7
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The prognosis for patients (pts) with r/r ALL is poor especially
after transplantation. Blinatumomab, an investigational
bispeciﬁc T-cell engager (BiTE) antibody construct that re-
directs T cells to CD19+ B cells resulting in serial lysis, has
shown antileukemia activity in pts with r/r ALL. We evalu-
ated the transplantation rate after blinatumomab-induced
remission, in pediatric patients with r/r ALL characterized by
negative prognostic factors, such as refractory disease and
prior alloHSCT.
In this single-arm study, eligible pts were 218 yrs old and
had an M3 marrow with B-precursor ALL that was refractory,
in 2nd marrow relapse, or any marrow relapse after HSCT;
and no CNS leukemia. A stepwise dose (wk 1: 5 mg/m2/d;
thereafter: 15 mg/m2/d) of blinatumomab was given by
continuous IV infusion (4 wks on/2wks off) for up to 5 cycles.
Primary endpoint was complete remission (CR) rate within 2
cycles. Secondary endpoints were alloHSCT rate, relapse-free
survival (RFS), overall survival (OS), and adverse events (AEs).
39 pts received blinatumomab. Median (range) age was 9
(2e16) yrs. 69% of pts had50% bonemarrow blasts. 41% had
1 prior salvage, 41% had 2 prior salvages and 18% were
primary refractory or had refractory relapse. 87% of pts
enrolled had relapsed within 6 months after the last remis-
sion. Among pts with prior alloHSCT (64%), 16% had 1 relapse
and 50% had 2 relapses. Of 12 pts (31%; 95% CI, 17%e48%)
who reached CR within the ﬁrst 2 cycles, 6 (50%) proceeded
to alloHSCT. 5 pts who did not respond to blinatumomab
received alloHSCT after treatment was ended. Donors
included haploidentical parents (n¼9), a sibling (n¼1) and an
unrelated donor (n¼1). AlloHSCT were performed at 8
different centers. Conditioning regimens included 5 mye-
loablative, 5 reduced intensity, and 1 unknown regimen.
Median (95% CI) RFS was 5.6 (2.6e12.1) months among bli-
natumomab responders and 6.5 (2.2e7.7) months among
responders receiving alloHSCT (measured from the time of
alloHSCT). At 6-month follow-up, median (95% CI) OSwas 4.3
(3.6e8.1) months among all pts and 7.7 (0.45eNE) months
among pts receiving alloHSCT (measured from the time of
alloHSCT).100-daymortality rate post alloHSCTwas 10%. The
most common AEs among all pts included pyrexia (74%),
anemia (33%), nausea (31%), headache (28%) and hyperten-
sion (26%). Anemia (26%), pyrexia (21%), increased alanine
aminotransferase or aspartate aminotransferase (18% each)
and febrile neutropenia (15%) were the most common grade
3 AEs. 3 (8%) pts (2 with grade 3 events) had cytokine-
release syndrome.
In this phase I/II study, blinatumomab has shown promising
antileukemia activity in pediatric patientswith r/r B-precursor
ALL, most of whom had prior alloHSCT and/or were refractory.
Half of pts who achieved CR in response to blinatumomabproceeded to alloHSCT, suggesting that blinatumomab may
provide a therapeutic option to bridge this patient population
to alloHSCT.243
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Background: Though there has been signiﬁcant improve-
ment in the outcome of adult patients with acute myeloid
leukemia (AML), much of this has been attributed to advance
in supportive care. Response to therapy has been a key pre-
dictor of clinical outcome in patients with newly diagnosed
AML. Published studies have identiﬁed prognostic factors in
predicting treatment response for AML induction therapy
but data is lacking in Asian population.
Objectives: To evaluate the response rates of conventional
induction chemotherapy in patients with AML in a tertiary
care hospital and to identify prognostic factors associated
with primary resistant AML.
Methods: This retrospective study included newly diag-
nosed AML patients who received conventional induction
chemotherapy at Singapore General Hospital between
January 1999 and June 2013. Primary outcome of the study
was to determine the response rates to treatment. Secondary
outcomes included duration of CR, relapse rate, overall sur-
vival (OS), and pre-treatment prognostic factors associated
with primary resistant AML. Primary resistant AML was
deﬁned as failure to achieve CR within two cycles of induc-
tion chemotherapy.
